Target intelligence / Profile preview

Peptidyl-prolyl cis-trans isomerase FKBP1A–Centrosomal protein of 250 kDa ternary complex (FKBP12–CEP250 complex)

Target
FKBP12–CEP250 complex
Molecular classification
Ternary complex, Molecular glue target, Protein-protein interaction, Immunophilin-target complex
01

Overview

The FKBP12–CEP250 ternary complex is a chemically induced protein-protein interaction formed by the recruitment of the cytosolic chaperone FKBP12 (Peptidyl-prolyl cis-trans isomerase FKBP1A) to the centrosomal protein 250 (CEP250, also known as C-Nap1) via a molecular glue (PNAS, 2020; NIH.gov). This interaction was first characterized using the natural product WDB002, which binds to the topologically flat coiled-coil domain of CEP250, a surface previously considered undruggable by conventional small molecules (ResearchGate, 2020). Biologically, the formation of this complex disrupts the normal function of CEP250 in maintaining centrosome cohesion, thereby interfering with NEK2-mediated centrosome separation during the cell cycle (Arxiv.org, 2025). This mechanism has therapeutic potential in oncology, where centrosome disruption can lead to cell cycle arrest or apoptosis in cancer cells (Revmed.com, 2020). Additionally, the complex has been explored for antiviral applications, as CEP250 is a known host interactor for the SARS-CoV-2 Nsp13 protein (RCSB.org, 2020). The discovery of this complex highlights the genetically programmable nature of FKBP12-mediated recognition, allowing small molecules to reprogram the chaperone to target diverse, previously inaccessible proteins (PNAS, 2020).

Other names
FKBP12–C-Nap1 complexFKBP12–CEP250–WDB002 complexFKBP1A–CEP250 complexFKBP12–CEP250 ternary complex
02

Mechanism of action

Molecular glue-induced proximity leading to disruption of centrosome cohesion and inhibition of NEK2-mediated centrosome separation

03

Biological functions

Centrosome cohesionCell cycle regulationCentrosome separationMicrotubule organizationProtein folding
04

Disease associations

CancerInfectionCOVID-19
05

Safety considerations

Off-target immunosuppressionGenotoxicity due to centrosome instabilityAneuploidyNephrotoxicity (potential, based on other FKBP12 ligands)
06

Interacting drugs

WDB002

2 more in the full profile.

07

Biomarkers

CEP250 expressionCentrosome fragmentationNEK2 activityCentrosome separation index

Beyond the preview

Go deeper on Peptidyl-prolyl cis-trans isomerase FKBP1A–Centrosomal protein of 250 kDa ternary complex (FKBP12–CEP250 complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase FKBP1A–Centrosomal protein of 250 kDa ternary complex (FKBP12–CEP250 complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call